Cero Therapeutics upgraded to Buy from Hold at D. Boral Capital

D. Boral Capital upgraded Cero Therapeutics (CERO) to Buy from Hold with a $30 price target With the reverse stock split behind the company and “several potential catalysts on the horizon,” Cero is positioned to achieve “rapid proof of concept, secure additional capital, and reach key inflection points that could drive meaningful stock appreciation,” the analyst tells investors in a research note. The firm says its positive outlook on Cero is based on the company’s “differentiated” approach to T cell engineering. It sees the shares as undervalued relative to the company’s innovation potential.